Innoviva reported strong growth in its infectious disease and critical care medicines, supported by increasing XACDURO sales and the commercial launch of Nuzolvence. However, a substantial non-cash decline in the value of healthcare investments produced a quarterly net loss despite improving operating profitability.
Innoviva’s XACDURO, ZEVTERA and NUZOLVENCE reach the 2026 Prix Galien finals, spotlighting a growing anti-infective portfolio.
Innoviva Specialty Therapeutics has received approval from the U.S. Food and Drug Administration for NUZOLVENCE (zoliflodacin), a first-in-class, single-dose oral antibiotic for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents. This approval, based on the largest-ever Phase 3 clinical trial for a new treatment against Neisseria gonorrhoeae, marks the first new oral gonorrhea